Serum anti-cyclic citrullinated peptide antibodies may predict disease activity in rheumatoid arthritis

Rheumatology International

Volumn 32, Issue 12, 2012, Pages 3799-3805

  Esalatmanesh, Kamal ^a   Jamali, Raika ^a   Jamali, Arsia ^b   Jamali, Bardia ^b   Nikbakht, Mohammadreza ^a  

^a KASHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antibodies; Anticyclic citrullinated peptide; Biomarkers; Disease activity; Rheumatoid arthritis

Indexed keywords

BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE ANTIBODY;

ADULT; ARTICLE; BLOOD LEVEL; DISEASE ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PEPTIDES, CYCLIC; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX;

EID: 84872262682     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-2282-3     Document Type: Article

References (32)

1. Davatchi F, Tehrani Banihashemi A, Gholami J, Faezi ST, Forouzanfar MH, Salesi M, Karimifar M, Essalatmanesh K, Barghamdi M, Noorolahzadeh E, Dahaghin S, Rasker JJ (2009) The prevalence of musculoskeletal complaints in a rural area in Iran: A WHO-ILAR COPCORD study (stage 1, rural study) in Iran. Clin Rheumatol 28:1267-1274
2. Zamani B, Jamali R, Ehteram H (2010) Synovial fluid adenosine deaminase and high-sensitivity C-reactive protein activity in differentiating monoarthritis. Rheumatol Int. doi:10.1007/ s00296-010-1602-3
3. Erer B, Yilmaz G, Yilmaz FM, Koklu S (2009) Assessment of adenosine deaminase levels in rheumatoid arthritis patients receiving anti-TNF-alpha therapy. Rheumatol Int 29:651-654
4. Zamani B, Jamali R, Jamali A (2011) Serum adenosine deaminase may predict disease activity in rheumatoid arthritis. Rheumatol Int. doi:10.1007/s00296- 011-1912-0
5. Fernandes RM, Silva NP, Sato EI (2011) Increased myeloperoxidase plasma levels in rheumatoid arthritis. Rheumatol Int. doi: 10.1007/s00296-011-1810-5
6. Miriovsky BJ, Michaud K, Thiele GM, O'Dell JR, Cannon GW, Kerr G, Richards JS, Johnson D, Caplan L, Reimold A, Hooker R, Mikuls TR (2010) Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis. Ann Rheum Dis 69:1292-1297
7. Rodríguez-Rodríguez L, Lamas JR, Varadé J, López-Romero P, Tornero-Esteban P, Abasolo L, de la Concha EG, Jover JA, Urcelay E, Fernández-Gutiérrez B (2011) Plasma soluble IL-6 receptor concentration in rheumatoid arthritis: Associations with the rs8192284 IL6R polymorphism and with disease activity. Rheumatol Int 31:409-413
8. Weinblatt ME, Keystone EC, Cohen MD, Freundlich B, Li J, Chon Y, Baumgartner SW (2011) Factors associated with radiographic progression in patients with rheumatoid arthritis who were treated with methotrexate. J Rheumatol 38:242-246
9. Emery P, Gabay C, Kraan M, Gomez-Reino J (2007) Evidencebased review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int 27:793-806
10. Cylwik B, Chrostek L, Gindzienska-Sieskiewicz E, Sierakowski S, Szmitkowski M (2010) Relationship between serum acutephase proteins and high disease activity in patients with rheumatoid arthritis. Adv Med Sci 55:80-85
11. Markatseli TE, Voulgari PV, Alamanos Y, Drosos AA (2011) Prognostic factors of radiological damage in rheumatoid arthritis: A 10-year retrospective study. J Rheumatol 38:44-52
12. Nishimoto N, Takagi N (2010) Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: Subanalysis of the SATORI study. Mod Rheumatol 20:539-547
13. Ryu HJ, Takeuchi F, Kuwata S, Kim YJ, Lee EY, Lee EB, Song YW (2011) The diagnostic utilities of anti-agalactosyl IgG antibodies, anti-cyclic citrullinated peptide antibodies, and rheumatoid factors in rheumatoid arthritis. Rheumatol Int 31:315-319
14. Onder B, Kurtaran A, Kimyon S, Selçuk B, Akyuz M (2009) Association of anti-CCP positivity with serum ferritin and DAS-28. Rheumatol Int 30:223-227
15. Landmann T, Kehl G, Bergner R (2010) The continuous measurement of anti-CCP-antibodies does not help to evaluate the disease activity in anti-CCP-antibody-positive patients with rheumatoid arthritis. Clin Rheumatol 29:1449-1453
16. Vanichapuntu M, Phuekfon P, Suwannalai P, Verasertniyom O, Nantiruj K, Janwityanujit S (2010) Are anti-citrulline autoantibodies better serum markers for rheumatoid arthritis than rheumatoid factor in Thai population? Rheumatol Int 30:755-759
17. Aridogan BC, Kaya S, Savaş S, Cetin ES, Akkuş S, Demirci M (2008) The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis. Mikrobiyol Bul 42:669-674
18. Serdaroglu M, Cakirbay H, Deger O, Cengiz S, Kul S (2008) The association of anti-CCP antibodies with disease activity in rheumatoid arthritis. Rheumatol Int 28:965-970
19. Sghiri R, Bouagina E, Zaglaoui H, Mestiri H, Harzallah L, Harrabi I, Ghannouchi M, Mokhtar F, Ghedira I (2007) Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis. Rheumatol Int 27:1125-1130
20. van der Heijde DM, van't Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB (1992) Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 51:177-181
21. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44-48
22. Shidara K, Inoue E, Hoshi D, Sato E, Nakajima A, Momohara S, Taniguchi A, Yamanaka H (2010) Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan. Rheumatol Int. doi:10.1007/s00296- 010-1671-3
23. Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN, Tsai CY, Chou CT (2006) The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 65:35-39
24. Inanc N, Dalkilic E, Kamali S, Kasapoglu-Gunal E, Elbir Y, Direskeneli H, Inanc M (2007) Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 26:17-23
25. Alexiou I, Germenis A, Ziogas A, Theodoridou K, Sakkas LI (2007) Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis. BMC Musculoskelet Disord: 8:37
26. Abdel-Nasser AM, Mahmoud MH, El Mansoury TM, Osman AM (2008) Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: Diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis. Scand J Rheumatol 37:329-336
27. Kolarz B, Majdan M, Dryglewska M, Darmochwal-Kolarz D (2010) Antibodies against cyclic citrullinated peptide don't decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis. Rheumatol Int. doi:10.1007/s00296-010-1509-z
28. Dejaco C, Duftner C, Klotz W, Schirmer M, Herold M (2010) Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-alpha treatment response in rheumatoid arthritis. Rheumatol Int 30:451-454
29. Caramaschi P, Biasi D, Tonolli E, Pieropan S, Martinelli N, Carletto A, Volpe A, Bambara LM (2005) Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int 26:58-62
30. Kogure T, Sato H, Kishi D, Ito T, Tatsumi T (2009) Serum levels of anti-cyclic citrullinated peptide antibodies are associated with a beneficial response to traditional herbal medicine (Kampo) in rheumatoid arthritis. Rheumatol Int 29:1441-1447
31. van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, Toes RE, n Mil AH (2009) Value of anti-modified citrullinated vimentin and thirdgeneration anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 60:2232-2241
32. Wagner E, Skoumal M, Bayer PM, Klaushofer K (2009) Antibody against mutated citrullinated vimentin: A new sensitive marker in the diagnosis of rheumatoid arthritis. Rheumatol Int 29:1315-1321